CT
METHODS: This ongoing, nonrandomized, open-label, pilot study is investigating HR and safety of epoetin alfa 80,000 U SC QW for up to 12 weeks (wks) in anemic (Hb <= 11 g/dL) pts with nonmyeloid malignancies undergoing CT. Primary end points are HR rates (minor: Hb increase >= 1-<2 g/dL from baseline [BL]; major: Hb increase >= 2 g/dL from BL), based on number of pts evaluable for a given week and independent of transfusion within 28 days.